Seagen Inc.

Genmab A+s

Msd International Gmbh

Shyra Gardai

Michael Feldhaus

Che-Leung Law

Lori Westendorf

Stanford L Peng

Matthew R Levengood

Vivian Trang

Jing Yang

Christopher Carosino

Che Leung-Law

Haley Neff-LaFord

Bianka Prinz

Esther C W Breij

Sandra Verploegen

Scott Peterson

Nicole Okeley

Reshma Abdulla Rangwala

Oyewale O Abidoye

Leonardo Viana Nicacio

Ryan Heiser

Anthony Cao

Courtney Beers

Phoenix Ho

Jessica Field

Julia C Piasecki

Thomas John Manley

Haley Neff-Laford

Stanford Peng

The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate

Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.

CD47 antibodies and uses thereof for treating cancer

Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.

T cells with reduced surface fucosylation and methods of making and using the same

The invention provides methods of treating cancer, such as myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with nonfucosylated anti-CD70 antibodies.

Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies

Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (K) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.

Anti-TIGIT antibodies

This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.

Dosage and administration of non-fucosylated anti-CD40 antibodies

Growing community of inventors

Bothell, WA, United States of America

Shyra Gardai